bd 1008 has been researched along with 4E2RCat in 1 studies
| Studies (bd 1008) | Trials (bd 1008) | Recent Studies (post-2010) (bd 1008) | Studies (4E2RCat) | Trials (4E2RCat) | Recent Studies (post-2010) (4E2RCat) |
|---|---|---|---|---|---|
| 28 | 0 | 4 | 6 | 0 | 1 |
| Protein | Taxonomy | bd 1008 (IC50) | 4E2RCat (IC50) |
|---|---|---|---|
| Mcl-1 | Homo sapiens (human) | 1.5746 | |
| eukaryotic translation initiation factor 4 gamma 1 isoform 4 | Homo sapiens (human) | 15.1 | |
| eukaryotic translation initiation factor 4E isoform 1 | Mus musculus (house mouse) | 15.1 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 1.7 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 1.7 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 1.7 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 1.7 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 1.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
1 other study(ies) available for bd 1008 and 4E2RCat
| Article | Year |
|---|---|
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |